Given their in vitro evidence that loss of NUDT5 led to TP resistance in ALL cells, it seems likely that loss-of-function somatic NUDT5 variants in ALL blast cells in vivo would compromise TP efficacy. This evidence concerns the gene NUDT5 and acute lymphoblastic leukemia.